Voluntis, an Aptar Pharma company and leader in digital therapeutics, announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight Care mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer.
This new solution will give patients of Voluntis’ digital therapeutics (DTx) platform access to OdySight Care and the possibility to measure their visual health anytime and anywhere. Once they have tested their vision using the OdySight Care application on their mobile device, patients will receive a clinically-validated visual acuity score in real-time, providing them with medical advice and guidance relating to their ophthalmic health.
Certain anti-cancer treatments such as chemotherapy or targeted immunotherapy are known for causing eye-related issues in some patients. Although ocular side effects such as a decrease in sharpness of vision may affect a patient’s quality of life and the ability to perform daily tasks such as reading or driving, most eye-related disorders caused by medical treatments can be managed with appropriate visual screening, monitoring, or the adjustment of treatment doses. Therefore, this new integrated solution, which provides a digital testing tool for cancer patients to self-assess their visual acuity while undergoing treatment, may help improve patient care and ultimately reduce the potential risk of treatment discontinuation.
Voluntis vision is to create an ecosystem of sensors and digital biomarkers
“We welcome this new partnership with Voluntis to expand our solutions to new specialties, where visual acuity testing, thanks to the existing OdySight platform, which now includes OdySight Care that can help manage the follow-up of patients. It is a key milestone in our technology platform development. We are excited to provide visual acuity testing to patients through the Theraxium platform,” said Edouard Gasser, chief executive officer, Tilak Healthcare.
“We are pleased to announce our new collaboration with Tilak Healthcare, which will expand Theraxium’s capabilities and integrate our platform into a broader digital health ecosystem.
This collaboration represents a new opportunity for patients to screen their visual acuity and access a better follow-up for their treatment-related symptoms,” added Pierre Leurent, chief executive officer, Voluntis and President, Aptar Pharma Digital Health.
This new collaboration further underlines Voluntis’ vision to create a comprehensive ecosystem of sensors and digital biomarkers around its DTx platform. Through such partnerships, Voluntis will make these advanced capabilities available to its life sciences partners, offering adaptable, turnkey digital therapeutic solutions that continuously improve the patient experience.